Key result
Rivaroxaban use in atrial fibrillation patients in clinical practice showed low rates of stroke (0.4), major bleeding (1.9), and intracranial bleeding (0.5 events per 100 patient-years).
Why the study?
What are the rates of stroke and bleeding in patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice?
Cohort
No
What are the rates of stroke and bleeding in patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice?
Real-world use of rivaroxaban in high-risk patients with nonvalvular atrial fibrillation demonstrates low rates of stroke and bleeding.
Supports low stroke/bleeding rates with rivaroxaban in real-world nonvalvular AF; hypothesis-generating and requires randomized confirmation.
AIM: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice. METHODS: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015. RESULTS: -VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively. CONCLUSION: In this cohort of AF patients anticoagulated with rivaroxaban, despite patients being older and having a high thromboembolic risk, rates of stroke, major bleeding and intracranial bleeding were low.
No takes yet. Share an insight, caveat, or question.
Martí et al. (2018) conducted a cohort in Atrial fibrillation. Rivaroxaban was evaluated on stroke, major bleeding and intracranial hemorrhage. Rivaroxaban use in atrial fibrillation patients in clinical practice showed low rates of stroke (0.4), major bleeding (1.9), and intracranial bleeding (0.5 events per 100 patient-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: